glp-1 without diabetes medications linked to major drop in pancreatic, colorectal cancer risk https://www.medicalnewstoday.com/articles/weight-loss-drugs-glp-1 -slash-risk-4-types-cancer-50-or-more-study GLP-1 RAs, Other Agents, Underused

That triggers a prior authorization request for the Bridge program, which the provider must complete to certify that the individual is eligible

Last reviewed: July 12, 2026 Last updated: July 12, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

doi: 10.1056/NEJMoa2032183 101 RubinoDMGreenwayFLKhalidUONeilPMRosenstockJSrrigRet al

Oral GLP-1 RAs are also under development, and early data show similar weight loss efficacy to semaglutide 2.4 mg [84], which could improve convenience and potentially reduce costs through improved manufacturing and distribution efficiency

Pharmaceutical companies are developing triple agonists that add glucagon agonism to GLP-1 and GIP